Sort by
Refine Your Search
-
Listed
-
Employer
-
Field
-
disease and to develop pioneering therapies benefiting the lives of patients in areas of unmet need. With more than 70 research groups and 800 employees, the Department of Biomedicine is the largest
-
disease and to develop pioneering therapies benefiting the lives of patients in areas of unmet need. With more than 70 research groups and 800 employees, the Department of Biomedicine is the largest
-
disease and to develop pioneering therapies benefiting the lives of patients in areas of unmet need. With more than 70 research groups and 800 employees, the Department of Biomedicine is the largest
-
invites exceptional candidates to apply for a postdoctoral position in pioneering projects developing synthetic biology-inspired human therapies. The D-BSSE is the first truly interdisciplinary research
-
: The project aims to develop a novel mechano-Raman imaging platform to map mechanical deformation in polymeric materials with high sensitivity. By combining the design of vibrational force probes with advanced
-
of Basel is an Academic Drug Discovery & Development Center, which comprehensively covers academic drug research throughout pre-clinical and clinical research phases. The Pharmaceutical Biology Group within
-
disease and to develop pioneering therapies benefiting the lives of patients in areas of unmet need. With more than 70 research groups and 800 employees, the Department of Biomedicine is the largest
-
leading role in developing and implementing predictive algorithms designed to identify those most at risk from extreme heat, as well as offering personalized adaptation advice --- translating rich multi
-
, bioelectrode device fabrication, and electrical engineering to develop bioelectronic interfaces enabling closed-loop programming of cellular behaviour and real-time monitoring of metabolic activity There will
-
. Empa is a research institution of the ETH Domain. For an applied research project, we are seeking a highly motivated Postdoc interested in the development of a hybrid AM manufacturing process for silicon